Actuate Therapeutics IncNASDAQ:ACTU
- LAST PRICE8.7600
- TODAY'S CHANGE (%)0.0100 (0.1143%)
- Bid / Lots3.4800/ 2
- Ask / Lots9.3000/ 23
- Open / Previous Close8.9200 / 8.7500
- Day Range
- 52 Week Range
- Volume56,761
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACTU |
|---|---|---|
| 09:32 ET | 7270 | 9 |
| 09:33 ET | 300 | 8.7 |
| 09:35 ET | 200 | 8.66 |
| 09:37 ET | 200 | 8.9 |
| 09:42 ET | 278 | 8.6824 |
| 09:53 ET | 100 | 8.61 |
| 10:08 ET | 100 | 8.64 |
| 10:13 ET | 2100 | 8.7499 |
| 10:15 ET | 200 | 8.84 |
| 10:18 ET | 2393 | 8.8248 |
| 10:24 ET | 251 | 8.78 |
| 11:02 ET | 250 | 8.825 |
| 11:05 ET | 100 | 8.76 |
| 11:18 ET | 358 | 8.75 |
| 11:54 ET | 100 | 8.66 |
| 11:56 ET | 700 | 8.61 |
| 11:57 ET | 443 | 8.65 |
| 12:14 ET | 550 | 8.61 |
| 12:17 ET | 100 | 8.6 |
| 01:33 ET | 192 | 8.34 |
| 01:38 ET | 1738 | 8.3 |
| 01:45 ET | 1890 | 8.15 |
| 01:47 ET | 1400 | 8.14 |
| 01:49 ET | 3283 | 8.1822 |
| 01:51 ET | 605 | 8.2 |
| 02:02 ET | 100 | 8.28 |
| 02:03 ET | 400 | 8.33 |
| 02:05 ET | 200 | 8.34 |
| 02:09 ET | 300 | 8.35 |
| 02:12 ET | 300 | 8.4 |
| 02:20 ET | 300 | 8.4 |
| 02:21 ET | 200 | 8.43 |
| 02:25 ET | 212 | 8.45 |
| 02:27 ET | 500 | 8.6 |
| 02:34 ET | 5812 | 8.3 |
| 03:03 ET | 950 | 8.48 |
| 03:12 ET | 450 | 8.5721 |
| 03:14 ET | 838 | 8.5457 |
| 03:15 ET | 600 | 8.5697 |
| 03:17 ET | 600 | 8.545 |
| 03:19 ET | 450 | 8.67 |
| 03:21 ET | 150 | 8.5401 |
| 03:24 ET | 850 | 8.5482 |
| 03:26 ET | 500 | 8.545 |
| 03:57 ET | 200 | 8.64 |
| 04:00 ET | 769 | 8.76 |
Oct 29, 2024
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development, from 6:39PM ET on Tuesday Oct 29, 2024 by Dow Jones
6:39PM ET on Tuesday Oct 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actuate Therapeutics Inc | 170.9M | 0.0x | --- |
Achieve Life Sciences Inc | 171.7M | -4.2x | --- |
Immutep Ltd | 257.9M | -7.9x | --- |
Skye Bioscience Inc | 165.0M | -1.5x | --- |
Galectin Therapeutics Inc | 176.9M | -3.8x | --- |
DiaMedica Therapeutics Inc | 178.5M | -8.2x | --- |
Company Information
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. Its lead program, Elraglusib Injection, is an intravenous solution of elraglusib for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib Injection has been evaluated in a Phase I dose escalation study (Actuate-1801 Part 1) in 238 adult patients. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Contact Information
- Headquarters
- 1751 RIVER RUN, SUITE 400FORT WORTH, TX, United States 76107
- Phone
- 847-986-4190
- Fax
- ---
Executives
- Chairman of the Board
- Aaron Fletcher
- President, Chief Executive Officer, Director
- Daniel Schmitt
- Chief Financial Officer
- Paul Lytle
- Chief Operating Officer
- Andrew Mazar
- Independent Director Nominee
- Jason Keyes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $170.9M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 19.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $-0.29 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
